Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95


Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram.

Zhang X, Hu P, Ding SY, Sun T, Liu L, Han S, DeLeo AB, Sadagopan A, Guo W, Wang X.

Am J Cancer Res. 2019 Jun 1;9(6):1266-1281. eCollection 2019.


Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.

Albers AE, Qian X, Kaufmann AM, Mytilineos D, Ferris RL, Hoffmann TK, DeLeo AB.

Sci Rep. 2018 Jul 16;8(1):10716. doi: 10.1038/s41598-018-29067-5.


Targeting cancer stem cells with p53 modulators.

Zhang Z, Liu L, Gomez-Casal R, Wang X, Hayashi R, Appella E, Kopelovich L, DeLeo AB.

Oncotarget. 2016 Jul 19;7(29):45079-45093. doi: 10.18632/oncotarget.8650.


Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice.

Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL.

Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19.


Blocking the formation of radiation-induced breast cancer stem cells.

Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li JJ, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X.

Oncotarget. 2014 Jun 15;5(11):3743-55.


PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.

Szczepanski MJ, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J, Whiteside TL.

Oral Oncol. 2013 Feb;49(2):144-51. doi: 10.1016/j.oraloncology.2012.08.005. Epub 2012 Sep 1.


17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Szajnik M, Szczepanski MJ, Elishaev E, Visus C, Lenzner D, Zabel M, Glura M, DeLeo AB, Whiteside TL.

Gynecol Oncol. 2012 Dec;127(3):587-94. doi: 10.1016/j.ygyno.2012.08.010. Epub 2012 Aug 17.


Targeting cancer stem cells with ALDH1A1-based immunotherapy.

Deleo AB.

Oncoimmunology. 2012 May 1;1(3):385-387.


A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.


Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, DeLeo AB, Wang X.

Clin Cancer Res. 2011 Oct 1;17(19):6174-84. doi: 10.1158/1078-0432.CCR-11-1111. Epub 2011 Aug 19.


Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.

Visus C, Ito D, Dhir R, Szczepanski MJ, Chang YJ, Latimer JJ, Grant SG, DeLeo AB.

Cancer Immunol Immunother. 2011 Jul;60(7):919-29. doi: 10.1007/s00262-011-1001-y. Epub 2011 Mar 16.


CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.

Andrade Filho PA, Ito D, Deleo AB, Ferris RL.

Cancer Immunol Immunother. 2010 Oct;59(10):1561-8. doi: 10.1007/s00262-010-0886-1. Epub 2010 Jun 25.


CSPG4 in cancer: multiple roles.

Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S.

Curr Mol Med. 2010 Jun;10(4):419-29. Review.


Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Hendrickson RC, Cicinnati VR, Albers A, Dworacki G, Gambotto A, Pagliano O, Tüting T, Mayordomo JI, Visus C, Appella E, Shabanowitz J, Hunt DF, DeLeo AB.

Cancer Immunol Immunother. 2010 Jan;59(1):113-24. doi: 10.1007/s00262-009-0730-7. Epub 2009 Jun 27.


Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer.

Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB, Whiteside TL.

Head Neck. 2009 Jun;31(6):773-81. doi: 10.1002/hed.21031.


CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Chikamatsu K, Sakakura K, Takahashi G, Okamoto A, Furuya N, Whiteside TL, DeLeo AB, Masuyama K.

Cancer Immunol Immunother. 2009 Sep;58(9):1441-8. doi: 10.1007/s00262-009-0661-3. Epub 2009 Jan 28.


Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

DeLeo AB, Whiteside TL.

Expert Rev Vaccines. 2008 Sep;7(7):1031-40. doi: 10.1586/14760584.7.7.1031. Review.


Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.

Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB.

Cancer Res. 2007 Nov 1;67(21):10538-45.


Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.

Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB.

Clin Immunol. 2007 Oct;125(1):43-51. Epub 2007 Jul 12.


Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.

Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB.

Int J Cancer. 2007 Jun 15;120(12):2618-24.


Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.

Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-Wilde H, Broelsch CE, DeLeo AB, Gerken G, Beckebaum S.

Int J Cancer. 2006 Dec 15;119(12):2851-60.


Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL.

J Immunol. 2006 Mar 15;176(6):3402-9.


Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.

Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL.

Cancer Immunol Immunother. 2005 Nov;54(11):1072-81. Epub 2005 Jun 16.


Impact of p53-based immunization on primary chemically-induced tumors.

Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tüting T, Kaczmarek E, DeLeo AB.

Int J Cancer. 2005 Mar 1;113(6):961-70.


P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.

Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB.

Cancer Res. 2003 Jul 1;63(13):3675-81.


Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL.

Cancer Res. 2002 Jun 15;62(12):3521-9.


Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, Welch WC.

J Neurooncol. 2001 Nov;55(2):91-100.


The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.

Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB.

J Immunol. 2002 Feb 1;168(3):1338-47.


Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope.

Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, Tüting T, Robbins PD, DeLeo AB.

Gene Ther. 2000 Dec;7(23):2036-40.


Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.

Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.

J Gene Med. 1999 Nov-Dec;1(6):400-6.


Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.

Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, Meyer EM, Rinaldo CR, DeLeo AB, Whiteside TL, Donnenberg AD.

Cytometry. 2000 Dec 1;41(4):321-8.


Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.

Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB.

J Immunol. 2000 Nov 15;165(10):5938-44.


A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.

Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB.

Clin Cancer Res. 2000 Mar;6(3):979-86.


Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.

Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB.

Clin Cancer Res. 1999 Jun;5(6):1281-8.


p53-based immunotherapy of cancer.

DeLeo AB.

Crit Rev Immunol. 1998;18(1-2):29-35. Review.


Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.

Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT.

Stem Cells. 1997;15(2):94-103. Review.


Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.

Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB.

J Exp Med. 1996 Apr 1;183(4):1357-65.


Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.


Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.

Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al.

Nat Med. 1995 Dec;1(12):1297-302.


Regulation of N-region diversity in Ig heavy chain transcripts expressed by murine fetal liver cells cultured with IL-7.

Appasamy PM, DeLeo AB, Weng Y, Kenniston TW Jr, Tang L, Burke MA.

Ann N Y Acad Sci. 1995 Sep 29;764:112-5. No abstract available.


Expression of diverse and functional TCR gamma and Ig heavy chain transcripts in fetal liver cells cultured with interleukin-7.

Appasamy PM, Weng Y, Kenniston TW Jr, Deleo AB, Tang L.

Mol Immunol. 1995 Aug;32(11):805-17.


Expression and function of Fc gamma RII on human natural killer cells.

Metes D, Galatiuc C, Moldovan I, Morel PA, Chambers WH, DeLeo AB, Rabinowich H, Schall R, Whiteside TL, Sulica A, et al.

Nat Immun. 1994 Nov-Dec;13(6):289-300.


Role of CD44 in the development of natural killer cells from precursors in long-term cultures of mouse bone marrow.

Delfino DV, Patrene KD, DeLeo AB, DeLeo R, Herberman RB, Boggs SS.

J Immunol. 1994 Jun 1;152(11):5171-9.


Tumor rejection antigens of the chemically induced BALB/c Meth A sarcoma.

DeLeo AB.

Immunol Ser. 1994;61:31-6. No abstract available.


Supplemental Content

Loading ...
Support Center